por
Gus Iversen, Editor in Chief | June 15, 2026
GT Medical Technologies has closed a $100 million Series E financing round as the company seeks to expand commercialization of its GammaTile brain tumor treatment and advance ongoing clinical research.
The Tempe, Arizona-based medical device company said the round was led by new investor Viking Global Investors and included participation from existing backers MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures.
According to the company, the financing was oversubscribed. Proceeds will be used to support commercial and operational initiatives following the release of data from the ROADS randomized controlled trial and to continue expansion of the BRIDGES trial in patients with newly diagnosed glioblastoma.
Ad Statistics
Times Displayed: 9690
Times Visited: 30 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
GammaTile is an FDA-cleared bioresorbable radiotherapy implant placed during brain tumor removal surgery. The device delivers radiation directly to the surgical cavity immediately after tumor resection, avoiding the delay that typically occurs before conventional radiation therapy can begin.
Data from the ROADS trial were presented at the 2026 American Society of Clinical Oncology annual meeting. The study evaluated GammaTile in patients with newly diagnosed brain metastases. The company reported that GammaTile reduced the risk of tumor recurrence and death at 12 months by 93% and 41%, respectively, compared with standard care.
Additional results showed a 12-month surgical bed recurrence rate of 1.3% in the GammaTile group versus 15.4% for standard care. Median surgical bed recurrence-free survival was not reached for patients receiving GammaTile, compared with 10.9 months for the control group. The company also reported a 24-month overall survival rate of 61.7% for GammaTile-treated patients, compared with 35.7% for those receiving standard care.
“This financing is validation of GammaTile's potential to be a standard of care treatment for operable brain tumors and will accelerate our ability to bring this important therapy to even more patients,” said Per Langoe, chief executive officer of GT Medical Technologies.
Reuters also recently reported on the ROADS trial findings, highlighting improved outcomes for patients who received the implant following brain tumor surgery.
Viking Global Investors manages approximately $52 billion across public and private investments, according to the firm.
